Welcome to our dedicated page for Pitanium SEC filings (Ticker: PTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pitanium's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pitanium's regulatory disclosures and financial reporting.
Pitanium Limited, a Hong Kong-based skincare and personal care retailer, reports that it received a Nasdaq delisting determination letter dated July 7, 2026. The notice follows an October 3, 2025 SEC order suspending trading in the company’s securities, which cited potential manipulation concerns involving recommendations by unknown persons via social media.
Unless Pitanium requests an appeal by July 14, 2026, Nasdaq plans to suspend trading at the opening on July 16, 2026 and subsequently file Form 25-NSE to remove the securities from listing and registration. The company states that Nasdaq has not communicated any findings that Pitanium engaged in wrongdoing, that its operations and financial condition are unaffected, and that its securities may later be eligible for trading on the over-the-counter market, without assurance of an active trading market.
Pitanium Limited is introducing two new personal care product lines under its Pitanium brand while addressing the status of a trading halt in its securities. The Pi-ology Series uses biotechnological skincare and fermentation techniques to enhance ingredient activity, purity, stability, penetrability, and longevity, aiming to improve skin compatibility and deeper nutrient delivery. The Pi-Formance Series focuses on internal wellness, with targeted supplements such as women’s probiotics and hair follicle health formulas designed to strengthen the body from within and complement skincare benefits. The company states that these products will roll out gradually and emphasizes that product descriptions are not medical claims. Separately, Pitanium reports it has submitted responses and supporting materials to Nasdaq’s latest information requests and has responded to all comments and document requests from the SEC, Nasdaq, and FINRA. The company notes that business operations remain normal and uninterrupted as of the report date.
Pitanium Ltd director Cheng Wai Hei filed an initial ownership report on Form 3. This filing establishes Cheng Wai Hei’s status as a director and starting point for future insider ownership and trading disclosures. The filing does not list any transactions or derivative positions.
Pitanium Ltd director Lui Achilles Cheong Lung filed an initial ownership report on Form 3. The filing does not list any common stock or derivative holdings and shows no buys, sells, option exercises, gifts, or other transactions. This is a routine compliance filing establishing his insider reporting status.
Pitanium Ltd director Lee Kui Gee Jennifer filed an initial Form 3 reporting beneficial ownership. The filing shows no reportable transactions or holdings, with zero buys, sells, exercises, gifts, or other changes disclosed. This is a baseline disclosure of insider ownership status at the time of becoming a reporting person.
Pitanium Ltd filed an initial insider ownership report for its Chief Financial Officer, Mok Yau. This Form 3 filing lists no stock or derivative transactions and shows no reported holdings in the excerpt, serving mainly as a baseline disclosure of the CFO’s status as an officer.
Pitanium Ltd director and 10% owner Young Yuen Yi reported existing shareholdings in a Form 3. The filing shows direct ownership of 8,333,330 Class A Ordinary Shares and 1,500,000 Class B Ordinary Shares following the reported positions. This is an initial ownership report and does not reflect new buy or sell transactions.
Pitanium Ltd director and Chief Executive Officer Wong Ying Yeung filed an initial ownership report showing substantial direct equity holdings. The filing reports 8,333,330 Class A Ordinary Shares and 1,500,000 Class B Ordinary Shares held directly after the reported date. This Form 3 does not reflect new purchases or sales; it establishes the executive’s starting ownership position as a more than ten percent shareholder.
Pitanium Limited, a Hong Kong–based beauty and personal care company, has filed its annual report on Form 20‑F for the fiscal year ended September 30, 2025.
Revenue decreased from HK$74.93 million in 2024 to HK$66.08 million in 2025, and gross profit declined from HK$60.82 million to HK$54.86 million, although gross margin improved from 81.17% to 83.02% due to changes in sourcing and packaging. The company highlights intense competition, supply‑chain dependence, logistics and warehouse risks, cybersecurity and data‑privacy exposure, and evolving PRC/Hong Kong regulatory oversight as key threats to its business model.
Pitanium’s Class A Ordinary Shares, listed on the Nasdaq Capital Market, are currently subject to a trading halt following a temporary SEC trading suspension in October 2025, creating uncertainty around liquidity, potential litigation exposure, future access to capital, and the ability to maintain Nasdaq listing compliance.
Pitanium Limited (PTNM) reports an update on the halt in trading of its shares on Nasdaq. Nasdaq originally halted trading on October 18, 2025, while it reviewed additional information it requested from the company. On November 7, 2025, Nasdaq requested further information and documents, and Pitanium responded in writing with supporting materials on November 13, 2025. The company states it is fully cooperating with Nasdaq, the U.S. Securities and Exchange Commission, and other regulators, and that the Group’s business operations remain normal and uninterrupted as of the date of this report.